Jefferies Reiterates Buy Rating on ANI Pharmaceuticals (ANIP) following Keenova report

Jefferies analyst Dennis Ding reiterated a Buy rating and $120.00 price target on ANI Pharmaceuticals (NASDAQ: ANIP)

The analyst commented, "Keenova reported "mid-teens" Acthar revenue growth for 2026, which is within our expected 15-25% yoy range. While we acknowledge it may be on the lower end, Keenova has been conservative on Acthar guidance (see exhibit) including most recently on Q3:25 EPS where the implied Q4 Acthar guide was flattish QoQ and they just posted a big $35M beat. The ACTH market will be >$1.3B in 2026 and the market should continue to grow +DD yoy where ANIP should benefit too"

For an analyst ratings summary and ratings history on ANI Pharmaceuticals click here. For more ratings news on ANI Pharmaceuticals click here.

Shares of ANI Pharmaceuticals closed at $73.71 yesterday.

You May Also Be Interested In

• DOJ Unveils $6.5B Healthcare Fraud Crackdown - WSJ
• Increasing unusual put volume: AVGX WMB FJET EWA NASA BSX DFTX ACI TE BURL HSBC RIO WRBY OBDC GT DRAM
• SpaceX (SPCX) call put ratio 1 calls to 1.1 puts as share price at $155